Palvella Therapeutics, Inc.

PVLA Healthcare Biotechnology

In the quarter to June 2026, EPS fell 76.7% and free cash flow fell 136.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.

120.30 7.04 −5.53%
Market cap
$1.8B
P/E
0.0×
Fwd P/E
−1.3×
Dividend yield
—
F-score
2/9
Altman Z
−11.49
Beneish M
1.44
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
6.49 5.20 28.88 21.18
Net Debt/EBITDA
6.25 5.13 17.63 11.71
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.71) (0.44) (0.83) (0.89)
Book value per Share
3.50 2.49 17.75 15.11
Free Cash Flow
(7.88) (4.93) (10.86) (12.84)
Other line items

Show all line items

Columns are period end dates